 The primary objective of the extension study is to assess long-term safety, with particular focus on the development of serious adverse events SAEs, adverse events of special interest AESIs including opportunistic infections and lymphoproliferative disease, and other immediately reportable events IREs, in subjects with recent-onset T1DM who complete CP-MGA031-01. 